170 related articles for article (PubMed ID: 20425627)
1. Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.
La Rochelle J; Amling CL
Curr Urol Rep; 2010 May; 11(3):198-201. PubMed ID: 20425627
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
[TBL] [Abstract][Full Text] [Related]
3. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
[TBL] [Abstract][Full Text] [Related]
4. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
Ilic D
Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
[TBL] [Abstract][Full Text] [Related]
6. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
7. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
8. ERSPC, PLCO studies and critique of cochrane review 2013.
Schröder FH
Recent Results Cancer Res; 2014; 202():59-63. PubMed ID: 24531778
[TBL] [Abstract][Full Text] [Related]
9. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
Wever EM; Draisma G; Heijnsdijk EA; Roobol MJ; Boer R; Otto SJ; de Koning HJ
J Natl Cancer Inst; 2010 Mar; 102(5):352-5. PubMed ID: 20142584
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
13. Problems with prostate-specific antigen screening: a critical review.
Schmid HP; Prikler L; Semjonow A
Recent Results Cancer Res; 2003; 163():226-31; discussion 264-6. PubMed ID: 12903857
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
[TBL] [Abstract][Full Text] [Related]
15. Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Luján M; Páez Á; Angulo JC; Granados R; Nevado M; Torres GM; Berenguer A
Actas Urol Esp; 2016 Apr; 40(3):164-72. PubMed ID: 26620123
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.
Rove KO; Crawford ED
World J Urol; 2012 Apr; 30(2):137-42. PubMed ID: 22116599
[TBL] [Abstract][Full Text] [Related]
17. The current state of prostate-specific antigen testing.
Lewis R; Hornberger B
JAAPA; 2016 Sep; 29(9):51-3. PubMed ID: 27575906
[TBL] [Abstract][Full Text] [Related]
18. ERSPC and PLCO prostate cancer screening studies: what are the differences?
Schröder FH; Roobol MJ
Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385
[No Abstract] [Full Text] [Related]
19. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
Pinsky PF; Prorok PC; Yu K; Kramer BS; Black A; Gohagan JK; Crawford ED; Grubb RL; Andriole GL
Cancer; 2017 Feb; 123(4):592-599. PubMed ID: 27911486
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
